Get started
6/16/25 - $lulu - Comment at low $240s6/16/25 :: VROCKSTAR :: NASDAQ:LULU Comment at low $240s - see comment from 6/6/25 about why $260 post EPS was "interesting" but not obvious to own ST - now we're only down a modest ~10% from there, so not much has really changed, except discretionary stocks have further drained. so this is not LULU specific per se, but sector/ factor beta - when you take LT leases out of the EV of ~29.3 bn as of writing, or about 1.5 bn = you get ~27.8 bn. when you consider PF capex is about 500 mm (ex growth)... you end up with FCF this year of ~1.5 bn. so 1.5/ 27.8 = 5.4%. - in the current macro where consumer has yet to really trough, or where we get "all clear cut to rates" (which is not my base case - if anything i think rates could stay sticky or even head higher in the ST), this means yield for this type of name post the last EPS comms might have to approach 6-7% all else equal - the mid teens PE of ~16x is "buy" (again referencing the last note), but in this sort of macro/ environment, 13...14...15x is also reasonable until the mkt can underwrite exactly where the "trough" will be and start to put a more comfortable '26 estimate on the stock (we're not there). - right now there are only three discretionary names i like in this order: NYSE:ANF > NYSE:YETI > $lulu. i only own NYSE:ANF b/c the FCF yield is nearly 15% on my est. and growth/ mgns also decent/ last EPS was "good". I trade around NYSE:YETI (don't currently own), and i see reason NASDAQ:LULU could get a ST bid here all else equal, so i'm playing a bit of a ST bounce here in the $240 region with some slight ITM option exposure for july. - however, i'm aware that the low is probably not in - and i've also seen this stock make nice mean reverting moves before it needs to find a lower level especially b/c the brand is great, the growth is not over... and eventually this will be a top tier discretionary name to own and the mkt is currently pricing it as such, anyway, at mid teens EPS when the rest of the B tier stuff is already single digits. *there's a reason for that*. - food for thought. V
NASDAQ:LULULong
by VROCKSTAR
4
NVDA 15mins Short Market Context: After a corrective decline, NVDA is showing temporary bullish momentum, forming higher lows on the lower timeframes. However, the overall structure remains bearish-biased, and this upside is likely part of a liquidity run rather than a genuine reversal. Liquidity Magnet at $149 There is resting liquidity above recent highs near $149, a zone where retail buy stops are likely positioned. Smart Money typically pushes price into such highs to induce late longs and liquidate early shorts before a major move. Momentum Shift Already in Progress The current bullish move lacks aggressive expansion — it's showing divergent momentum and weaker impulse candles compared to the prior leg down. This signals the upside may terminate as a liquidity hunt, not trend continuation. Structural Setup for the Short Once price taps $149, observe for a sharp rejection or breakdown of internal short-term structure (i.e., break of a local low with displacement). This signals the smart money exit and bearish intent. The shift from engineered buy-side pressure into sell-side delivery confirms short bias. I expect NVDA to run higher into $149 to sweep liquidity, then break down sharply toward $135. I will look for internal bearish structure to form right after the sweep and will short only upon confirmation of intent (displacement and lower low).
NASDAQ:NVDAShort
by ProSignalai
6/16/25 - $qubt - 20% short. ice cold veins.6/16/25 :: VROCKSTAR :: NASDAQ:QUBT 20% short. ice cold veins. - puts/ size managed approps. - be warned, this company won't likely ever deliver a product. - therefore, it's very likely worth exactly zero. - i'll take it to 30% if i need to in the next few sessions leading up to it's "index inclusion" where it will get absolutely decimated as funds find it an "easy" funding short on the mgn. - mgmt will have a hard time testifying in court why they are making various misleading statements which are likely fraudulent and at worst criminal. but that's just a guess. - alas who knows. - i don't have a crystal ball - but i know a donut when i see one. V
NASDAQ:QUBTShort
by VROCKSTAR
2
ZIMV Medical's bashed down +100% Long Term opportunity?Medical Stocks have been bashed of late. All Medicals remain highly speculative, but can provided huge upside for the risky Investor or Trader. Studying the PA (Price Action) and the Trend Curve can offer one entry positions. Support and resistance Zones show a potential nice 100% upside. As always if you are unsure, please consult with your own personal investment Advisor before making any Trades or Investments as most are 12 months or more views. Should you apreciate my comments and chart studies - please smash that like button. It's just a click away. Regards Graham
NASDAQ:ZIMVLong
by hitchcoxg
AMD First touch of 1W MA50 after 8 months!Advanced Micro Devices (AMD) hit today its 1W MA50 (blue trend-line) for the first time in almost 8 months (since October 28 2024). This is a crucial test as the las time this level broke as a Resistance following a Channel Up bottom rebound was on the week of January 30 2023. When that happened, the Bullish Leg extended the upside to complete a +143.12% rise, before the next 1W MA50 pull-back. As a result, if we close the week above the 1W MA50, we expect to see $185 before the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:AMDLong
by TradingShot
1
MGP Ingredients | MGPI | Long at $29.57MGP Ingredients NASDAQ:MGPI has been in "crash" phase since 2023 due to lower U.S. liquor consumption, a whiskey glut, a CEO resignation, a facility closure, and a shift to higher-margin business. While currently trading near $30, the book value is at $39, forward price-to-earnings is 8x, debt-to-equity is 0.4x (low), and some insiders have been awarded stocks and options (although, selling has been rather high, too). Earnings and revenue are expected to grow slowly beyond 2025, but this year is anticipated to be the worst in some time. The low expectations may already be priced in, but time will tell. While I do not plan to be a long-term holder of the stock, the price is within my "crash" simple moving average area and the fundamentals aren't terrible. If interest rates are lowered within the next year, I believe this could begin the turnaround for the company (although slow). Thus, at $29.57, NASDAQ:MGPI is in a personal buy zone for a swing trade. Targets: $35.00 (+18.4%) $40.00 (+35.3%)
NASDAQ:MGPILong
by WorthlessViews
QFIN (360 DigiTech) - Undervalued Growth Play with Strong UpsideTicker: QFIN (NASDAQ) Recommendation: BUY Current Price: $42.93 Entry Zone: $42 - $43 (Pullback to support) Stop Loss: $39 (-9.2% from entry, below key swing low) Take Profit: $50.70 (+18.1% upside) Risk/Reward Ratio: 1:2 📈 Technical Analysis Trend: Mixed but stabilizing (Daily: Neutral, 4H/1H: Recent weakness). Key Levels: Support: $41.50 (SMA-50), $39 (Strong demand zone). Resistance: $43.50 (Recent high), $50.70 (2025 YTD resistance). Indicators: RSI (Daily): 53.16 (Neutral, no overbought/oversold signal). MACD: Approaching bullish crossover on daily chart. Volume: Light selling pressure, accumulation possible near support. 💡 Fundamental Catalyst Deep Value Metrics: P/E Ratio: 6.57 (Sector avg: ~20x) P/B Ratio: 0.25 (Extremely undervalued) Zero Debt: Debt-to-Equity of 0, pristine balance sheet. Growth Potential: Fintech sector rebound, China regulatory easing hopes. 🎯 Why This Trade? Extreme Undervaluation: P/B < 0.3 signals potential mean reversion. Technically Oversold: RSI2 Connors signaled accumulation recently. Asymmetric Risk/Reward: Limited downside (strong $39 support) vs. 20%+ upside. ⚡ Trade Management Confirmation Needed: Wait for break above $43.50 with volume. Add-on: Consider at $45 if momentum builds. Trailing Stop: Move SL to $41 after TP1 at $47. 📉 Risks: China macroeconomic/regulatory risks. Low liquidity → Wider spreads. ✅ Verdict: QFIN is a high-risk, high-reward play for value hunters. Ideal for swing traders with patience. Like & Follow for more under-the-radar gems! 🔍 #QFIN #Fintech #Undervalued #ValueInvesting
NASDAQ:QFINLong
by marjaku
TSM (Taiwan Semiconductor)-Breakout Play with Strong FundamentaTicker: TSM (NYSE) Recommendation: BUY Current Price: $216.62 Entry Zone: $216 - $218 (Breakout confirmation) Stop Loss: $190 (Key support level, -12.3% from entry) Take Profit: $270.04 (+24.7% upside) Risk/Reward Ratio: 1:2 📈 Technical Analysis Trend: Strong bullish momentum across all timeframes (Daily/4H/1H). Key Levels: Support: $200 (SMA-50), $190 (Major swing low). Resistance: $218 (Bollinger High), $270 (Fibonacci extension). Indicators: RSI (Daily): 72.98 (Approaching overbought but with room to run in strong trends). MACD: Bullish crossover, positive momentum. Volume: Rising on upward moves, confirming buyer interest. 💡 Fundamental Catalyst Strong Growth: Revenue +33.8% YoY, Net Income +36% YoY. Undervalued Metrics: P/S Ratio of 0.35 (Sector avg: ~5.0). Low Debt: Debt-to-Equity of 0.22, Interest Coverage Ratio of 174x. 🎯 Why This Trade? Breakout Potential: TSM is testing multi-week highs with volume support. Semiconductor Sector Strength: NVDA/AMD leading sector rally, TSM as a key supplier. High Reward/Risk: Clear SL level with 2x upside potential. ⚡ Trade Management Add-on: Consider adding at $225 if momentum continues. Trailing Stop: Move SL to breakeven at $220 if price reaches $240. Watchlist: Monitor NASDAQ/SOX index correlation. 📉 Risks: Broad market pullback. Geopolitical tensions (Taiwan exposure). ✅ Verdict: TSM combines technical breakout strength with undervalued fundamentals. A high-conviction trade for swing traders. Like & Follow for more data-driven ideas! 🔥 #TSM #Semiconductors #Breakout #Investing
NYSE:TSMLong
by marjaku
1
ORCL at a Critical Zone: Will the Eagle Strike? Oracle (ORCL) just completed a parabolic +20% move. Now it's flashing clear signs of exhaustion: Bearish candle forming just below the EMA21 RSI spiked above 80 and is now curling down Volume is fading while price stalls Long upper wicks = visible selling pressure This setup fits perfectly with my strategy: “The Eagle Trap” 🦅 — designed to catch short-term tops after euphoric rallies. 🔻 PUT thesis: If price breaks below $212 with strong volume, targets are: $208 → $202 → $198. 🎯 Invalidation: If it reclaims $217 with heavy volume, the trade is off. I don’t force trades — but I’m ready to strike if the breakdown confirms. 🔔 Follow me for real setups, weekly traps, and full strategy breakdowns.
NYSE:ORCLShort
by perezliz37
Hut 8 Corp (HUT) From Miner to Digital Infrastructure PowerhouseCompany Overview: Hut 8 NASDAQ:HUT is transforming into a next-gen digital infrastructure leader, blending Bitcoin mining, AI compute, and cloud services for diversified, long-term growth. Key Catalysts: Major Operational Upgrades ⛏️ 79% QoQ jump in deployed hashrate and 37% fleet efficiency gain in Q1 2025. Positions HUT for cost-effective BTC production as crypto markets rebound. Massive Bitcoin Reserves ₿ 10,264 BTC on balance sheet (~$847M as of Mar 31, 2025). Acts as a digital asset custodian + infrastructure operator, offering leveraged upside to BTC. Diversification into Compute & AI Infrastructure 🧠 Q1 Digital Infrastructure + Compute revenue tops $21M. Reduces mining dependency and captures tailwinds from AI and HPC demand. Investment Outlook: Bullish Case: We remain bullish on HUT above $15.00–$16.00. Upside Target: $30.00–$32.00, driven by crypto exposure, AI-driven growth, and operational scaling. ⚙️ Hut 8 – Mining the Future of Digital Infrastructure. #HUT #Bitcoin #CryptoMining #DigitalInfrastructure #AICompute #HPC #Web3 #BTCExposure
NASDAQ:HUTLong
by Richtv_official
Descending Triangle in Apple?Apple has struggled all year, and evidence of a downtrend may be growing in the tech giant. The first pattern on today’s chart is this month’s lower high relative to mid-May. Combined with the May 7 low of $193.25, some traders may think a descending triangle is taking shape. That’s a potentially bearish formation. Second, TradeStation data shows that AAPL is the only trillion-dollar company now trading below its 200-day simple moving average (SMA). The 200-day SMA has also turned lower. Those points may confirm long-term price action is less bullish. Next, prices remaining below the falling 50-day SMA may signal intermediate-term weakness. Fourth, short-term trends may be weakening: The 8-day exponential moving average (EMA) is below the 21-day EMA and MACD is falling. Finally, AAPL is one of the most active underliers in the options market. That could help traders take positions with calls and puts. Check out TradingView's The Leap competition sponsored by TradeStation. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com . Visit www.TradeStation.com for full details on the costs and fees associated with options. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com . TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:AAPL
by TradeStation
Integra LifeSciences Holdings | IART | Long at $12.39Integra LifeSciences Holdings Corp NASDAQ:IART manufactures and sells surgical instruments, neurosurgical products, and wound care solutions for neurosurgery, neurocritical care, otolaryngology, orthopedics, and general surgery. The stock has fallen over the past few years due to earnings misses / lowered earnings per share guidance, slow revenue growth, and operational challenges / recalls. But the company has been around since 1989 (endured many ups and downs during that time), has over 4,000 employees, a book value near $20 (undervalued), a forward price-to-earnings between 6x-9x (depending on the source), and revenue growth beyond 2025 and into 2028. Debt is slightly high with a debt-to-equity ratio of 1.2x and a quick ratio near 0.8x (company may have difficulty meeting its short-term obligations with its most liquid assets), it is thus a risky play. But the valuation and potential turnaround should get some attention. From a technical analysis perspective, the stock price has entered and exited my "crash" simple moving average area 3 times now (see green lines). While I think $10 is likely in the near-term, it appears the stock *may* be forming a bottom - especially given the book value is more than 60% from the current price. But, as always, medical device stocks are always a major investment risk, so due diligence is needed. Thus, at $12.39, NASDAQ:IART is in a buy zone with a note regarding the potential for a dip near $10 before a move up. Targets will be kept low for a swing trade. Targets: $15.00 (+21.0%) $16.50 (+33.2%)
NASDAQ:IARTLong
by WorthlessViews